BioCryst Pharmaceuticals Inc (BCRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioCryst Pharmaceuticals Inc (BCRX) has a cash flow conversion efficiency ratio of 0.112x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.14 Million) by net assets ($-553.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check BioCryst Pharmaceuticals Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
BioCryst Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how BioCryst Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See BCRX net asset value for net asset value and shareholders' equity analysis.
BioCryst Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioCryst Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
COUNTRY GARDEN SVDL-0001
F:75H
|
N/A |
|
African Rainbow Minerals Ltd
JSE:ARI
|
0.058x |
|
BTG Hotels Group Co Ltd
SHG:600258
|
0.084x |
|
Aguas Andinas S.A
SN:AGUAS-A
|
0.049x |
|
Mr Price Group Ltd
JSE:MRP
|
0.218x |
|
ODFJELL DRILL.LTD. DL-01
F:OD3
|
0.081x |
|
SK Bioscience Co Ltd
KO:302440
|
0.010x |
|
Driven Brands Holdings Inc
NASDAQ:DRVN
|
0.100x |
Annual Cash Flow Conversion Efficiency for BioCryst Pharmaceuticals Inc (1994–2025)
The table below shows the annual cash flow conversion efficiency of BioCryst Pharmaceuticals Inc from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see how much is BioCryst Pharmaceuticals Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-119.15 Million | $329.88 Million | -2.769x | -2632.95% |
| 2024-12-31 | $-475.93 Million | $-52.02 Million | 0.109x | -47.67% |
| 2023-12-31 | $-455.53 Million | $-95.14 Million | 0.209x | -61.98% |
| 2022-12-31 | $-294.60 Million | $-161.85 Million | 0.549x | -58.65% |
| 2021-12-31 | $-106.99 Million | $-142.16 Million | 1.329x | -81.35% |
| 2020-12-31 | $-19.26 Million | $-137.22 Million | 7.124x | +404.18% |
| 2019-12-31 | $38.25 Million | $-89.58 Million | -2.342x | -24.57% |
| 2018-12-31 | $49.23 Million | $-92.56 Million | -1.880x | -282.78% |
| 2017-12-31 | $83.77 Million | $-41.14 Million | -0.491x | +98.55% |
| 2016-12-31 | $1.58 Million | $-53.44 Million | -33.864x | -12221.93% |
| 2015-12-31 | $47.72 Million | $-13.12 Million | -0.275x | +46.08% |
| 2014-12-31 | $75.64 Million | $-38.55 Million | -0.510x | -102.16% |
| 2013-12-31 | $-1.13 Million | $-26.53 Million | 23.561x | -71.40% |
| 2012-12-31 | $-454.00K | $-37.40 Million | 82.372x | +3881.60% |
| 2011-12-31 | $14.81 Million | $-32.25 Million | -2.178x | -408.23% |
| 2010-12-31 | $66.62 Million | $-28.55 Million | -0.429x | -127.97% |
| 2009-12-31 | $86.27 Million | $-16.22 Million | -0.188x | +58.19% |
| 2008-12-31 | $46.43 Million | $-20.87 Million | -0.450x | -16.74% |
| 2007-12-31 | $64.91 Million | $-25.00 Million | -0.385x | +46.44% |
| 2006-12-31 | $21.16 Million | $-15.21 Million | -0.719x | -79.99% |
| 2005-12-31 | $58.44 Million | $-23.35 Million | -0.399x | +35.44% |
| 2004-12-31 | $29.33 Million | $-18.15 Million | -0.619x | -57.22% |
| 2003-12-31 | $28.45 Million | $-11.20 Million | -0.394x | +3.49% |
| 2002-12-31 | $40.13 Million | $-16.36 Million | -0.408x | -128.07% |
| 2001-12-31 | $56.81 Million | $-10.16 Million | -0.179x | -245.95% |
| 2000-12-31 | $61.48 Million | $-3.18 Million | -0.052x | +24.69% |
| 1999-12-31 | $71.40 Million | $-4.90 Million | -0.069x | +54.74% |
| 1998-12-31 | $27.70 Million | $-4.20 Million | -0.152x | +62.76% |
| 1997-12-31 | $25.30 Million | $-10.30 Million | -0.407x | -111.94% |
| 1996-12-31 | $35.40 Million | $-6.80 Million | -0.192x | +71.81% |
| 1995-12-31 | $11.30 Million | $-7.70 Million | -0.681x | -17.41% |
| 1994-12-31 | $11.20 Million | $-6.50 Million | -0.580x | -- |
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more